Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

Abstract Alveolar soft part sarcoma (ASPS) is an ultra-rare, highly angiogenic sarcoma with limited responsiveness to chemotherapy. Tyrosine kinase inhibitors (TKIs) such as sunitinib and pazopanib have shown promising activity, but comparative real-world data remain scarce. This multicenter, retros...

Descripción completa

Detalles Bibliográficos

Autores principales:	Zehra Sucuoğlu İşleyen, Seval Ay, Ertuğrul Bayram, Şaban Seçmeler, Oğuzhan Selvi, Saadettin Kılıçkap, Deniz Can Güven, Sabin Göktaş Aydın, Teoman Sakalar, Metin Pehlivan, Serkan Keskin, Olçun Ümit Ünal, Serkan Menekşe, Engin Kut, Eyyup Çavdar, Özlem Aydın İsak, İsmail Ertürk, Emre Hafızoğlu, Murat Ayhan, Nurgül Yaşar, Seval Orman, Hatice Asoğlu Rüzgar, Reşit Akyel, Mert Başaran, Kayhan Ertürk, M. Mustafa Atcı, Emir Çelik
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2025-11-01
Colección:	Scientific Reports
Materias:	Alveolar soft part sarcoma Sunitinib Pazopanib Tyrosine kinase inhibitor Anti-angiogenic therapy
Acceso en línea:	https://doi.org/10.1038/s41598-025-29276-9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!